Primary Care Tips to Help Patients Lose Weight

Primary Viewpoints: Immunizations with Dr Steven P. Furr

The novel therapy combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.

Keith A. Reynolds

October 1st 2024

Dupilumab Drug Survival Rates Superior to Those for Upadacitinib and Tralokinumab in Atopic Dermatitis: Large-Scale, Real-World Data

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Grace Halsey

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

A first large-scale comparison of length of treatment with advanced AD therapies also identified reasons for discontinuation and examined prior use of biologics and JAK inhibitors.

October 25th 2023

FDA Grants Priority Review to Brensocatib, First Targeted Treatment for Bronchiectasis

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Patient Care Editorial Staff

US Dementia Cases to Double by 2060: Daily Dose

The FDA has set the Prescription Drug User Fee Act target action date for bronchiectasis for August 12, 2025, Insmed Incorporated announced.

FDA Approves AbbVie's Combination Antibiotic Emblaveo for Complicated Intra-Abdominal Infections

Your daily dose of the clinical news you may have missed.

Related Content

Primary Viewpoints: Immunizations with Dr Steven P. Furr

The novel therapy combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.

Keith A. Reynolds

October 1st 2024

Dupilumab Drug Survival Rates Superior to Those for Upadacitinib and Tralokinumab in Atopic Dermatitis: Large-Scale, Real-World Data

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Grace Halsey

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

A first large-scale comparison of length of treatment with advanced AD therapies also identified reasons for discontinuation and examined prior use of biologics and JAK inhibitors.

October 25th 2023

FDA Grants Priority Review to Brensocatib, First Targeted Treatment for Bronchiectasis

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Patient Care Editorial Staff

US Dementia Cases to Double by 2060: Daily Dose

The FDA has set the Prescription Drug User Fee Act target action date for bronchiectasis for August 12, 2025, Insmed Incorporated announced.